Donor safety confirmed.
作者信息
Szer Jeff
机构信息
Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Australia.
出版信息
Blood Adv. 2024 Aug 13;8(15):4194-4195. doi: 10.1182/bloodadvances.2024013477.
Abstract
摘要
相似文献
1
Donor safety confirmed.
Blood Adv. 2024 Aug 13;8(15):4194-4195. doi: 10.1182/bloodadvances.2024013477.
2
[Donor exclusions, discarded blood and transfusion unsuited blood conserves of 2,13 million potential blood donors 1991 to 1994].
Beitr Infusionsther Transfusionsmed. 1996;33:81-92.
3
Review of blood donor deferral with emphasis on donor and patient safety.
Transfus Clin Biol. 2023 Feb;30(1):56-62. doi: 10.1016/j.tracli.2022.07.002. Epub 2022 Jul 11.
4
Pandemic blood donor demographics - Do changes impact blood safety?
Transfusion. 2021 May;61(5):1389-1393. doi: 10.1111/trf.16320. Epub 2021 Feb 20.
5
Re-engineering the medical assessment of blood donors in South Africa: The balance between supply and safety.
Transfusion. 2021 Dec;61(12):3361-3371. doi: 10.1111/trf.16702. Epub 2021 Oct 13.
6
Donor deferral and resulting donor loss at the American Red Cross Blood Services, 2001 through 2006.
Transfusion. 2008 Dec;48(12):2531-9. doi: 10.1111/j.1537-2995.2008.01903.x. Epub 2008 Aug 20.
7
The impact of donor selection on blood safety in Iran.
Transfus Apher Sci. 2012 Aug;47(1):13-6. doi: 10.1016/j.transci.2012.03.001. Epub 2012 Apr 20.
8
The Lombardy Rare Donor Programme.
Blood Transfus. 2014 Jan;12 Suppl 1(Suppl 1):s249-55. doi: 10.2450/2013.0182-12. Epub 2013 Feb 21.
9
Motivation, blood donor satisfaction and intention to return during the COVID-19 pandemic.
Vox Sang. 2022 Apr;117(4):488-494. doi: 10.1111/vox.13212. Epub 2021 Nov 2.
10
Safety and donor acceptance of an abbreviated donor history questionnaire.
Transfusion. 2006 Oct;46(10):1745-53. doi: 10.1111/j.1537-2995.2006.00967.x.
本文引用的文献
1
Long-term outcomes of peripheral blood stem cell unrelated donors mobilized with filgrastim.
Blood Adv. 2024 Aug 13;8(15):4196-4206. doi: 10.1182/bloodadvances.2024012646.
2
An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia.
Transplant Cell Ther. 2023 Apr;29(4):279.e1-279.e10. doi: 10.1016/j.jtct.2022.12.013. Epub 2022 Dec 23.
3
The case for plerixafor to replace filgrastim as the optimal agent to mobilize peripheral blood donors for allogeneic hematopoietic cell transplantation.
Exp Hematol. 2019 Feb;70:1-9. doi: 10.1016/j.exphem.2018.11.003. Epub 2018 Nov 11.
4
Towards a global system of vigilance and surveillance in unrelated donors of haematopoietic progenitor cells for transplantation.
Bone Marrow Transplant. 2013 Nov;48(12):1506-9. doi: 10.1038/bmt.2013.104. Epub 2013 Jul 29.
5
Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project.
Br J Haematol. 2006 Dec;135(5):642-50. doi: 10.1111/j.1365-2141.2006.06312.x. Epub 2006 Oct 19.
6
Therapy with granulocyte colony-stimulating factor in systemic lupus erythematosus may be associated with severe flares.
J Rheumatol. 2006 Sep;33(9):1878-80. Epub 2006 Jul 1.
7
Granulocyte colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells.
Exp Hematol. 2004 Jan;32(1):122-30. doi: 10.1016/j.exphem.2003.09.007.
8
Three to six year follow-up of normal donors who received recombinant human granulocyte colony-stimulating factor.
Bone Marrow Transplant. 2000 Jan;25(1):85-9. doi: 10.1038/sj.bmt.1702072.
9
10
Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients.
Blood. 1988 Dec;72(6):2074-81.
Zotero 插件